229 related articles for article (PubMed ID: 25533429)
1. Effects of ursodeoxycholic acid therapy on carotid intima media thickness, apolipoprotein A1, apolipoprotein B, and apolipoprotein B/A1 ratio in nonalcoholic steatohepatitis.
Ozel Coskun BD; Yucesoy M; Gursoy S; Baskol M; Yurci A; Yagbasan A; Doğan S; Baskol G
Eur J Gastroenterol Hepatol; 2015 Feb; 27(2):142-9. PubMed ID: 25533429
[TBL] [Abstract][Full Text] [Related]
2. The associations between apolipoprotein B, A1, and the B/A1 ratio and nonalcoholic fatty liver disease in both normal-weight and overweight Korean population.
Yang MH; Sung J; Gwak GY
J Clin Lipidol; 2016; 10(2):289-98. PubMed ID: 27055959
[TBL] [Abstract][Full Text] [Related]
3. Omega-3 polyunsaturated fatty acid and ursodeoxycholic acid have an additive effect in attenuating diet-induced nonalcoholic steatohepatitis in mice.
Kim JK; Lee KS; Lee DK; Lee SY; Chang HY; Choi J; Lee JI
Exp Mol Med; 2014 Dec; 46(12):e127. PubMed ID: 25523099
[TBL] [Abstract][Full Text] [Related]
4. Hepatic Steatosis and Insulin Resistance, But Not Steatohepatitis, Promote Atherogenic Dyslipidemia in NAFLD.
Bril F; Sninsky JJ; Baca AM; Superko HR; Portillo Sanchez P; Biernacki D; Maximos M; Lomonaco R; Orsak B; Suman A; Weber MH; McPhaul MJ; Cusi K
J Clin Endocrinol Metab; 2016 Feb; 101(2):644-52. PubMed ID: 26672634
[TBL] [Abstract][Full Text] [Related]
5. Randomized placebo-controlled trial of ursodeoxycholic acid with vitamin e in nonalcoholic steatohepatitis.
Dufour JF; Oneta CM; Gonvers JJ; Bihl F; Cerny A; Cereda JM; Zala JF; Helbling B; Steuerwald M; Zimmermann A;
Clin Gastroenterol Hepatol; 2006 Dec; 4(12):1537-43. PubMed ID: 17162245
[TBL] [Abstract][Full Text] [Related]
6. A two-year clinical study of the effects of two triphasic oral contraceptives on plasma lipids.
Kakis G; Powell M; Marshall A; Woutersz TB; Steiner G
Int J Fertil Menopausal Stud; 1994; 39(5):283-91. PubMed ID: 7820162
[TBL] [Abstract][Full Text] [Related]
7. Ursodeoxycholic acid as a means of preventing atherosclerosis, steatosis and liver fibrosis in patients with nonalcoholic fatty liver disease.
Nadinskaia M; Maevskaya M; Ivashkin V; Kodzoeva K; Pirogova I; Chesnokov E; Nersesov A; Kaibullayeva J; Konysbekova A; Raissova A; Khamrabaeva F; Zueva E
World J Gastroenterol; 2021 Mar; 27(10):959-975. PubMed ID: 33776366
[TBL] [Abstract][Full Text] [Related]
8. Association of carotid intima media thickness with atherogenic index of plasma, apo B/apo A-I ratio and paraoxonase activity in patients with non-alcoholic fatty liver disease.
Fadaei R; Meshkani R; Poustchi H; Fallah S; Moradi N; Panahi G; Merat S; Golmohammadi T
Arch Physiol Biochem; 2019 Feb; 125(1):19-24. PubMed ID: 29359590
[TBL] [Abstract][Full Text] [Related]
9. Nonalcoholic steatohepatitis associated with metabolic syndrome: relationship to insulin resistance and liver histology.
Jung KY; Cho SY; Kim HJ; Kim SB; Song IH
J Clin Gastroenterol; 2014; 48(10):883-8. PubMed ID: 24440936
[TBL] [Abstract][Full Text] [Related]
10. Treatment of NASH with ursodeoxycholic acid: cons.
Liechti F; Dufour JF
Clin Res Hepatol Gastroenterol; 2012 Sep; 36 Suppl 1():S46-52. PubMed ID: 23141894
[TBL] [Abstract][Full Text] [Related]
11. Comparison of the effects of simultaneous administration of vitamin C and omega-3 fatty acids on lipoproteins, apo A-I, apo B, and malondialdehyde in hyperlipidemic patients.
Shidfar F; Keshavarz A; Jallali M; Miri R; Eshraghian M
Int J Vitam Nutr Res; 2003 May; 73(3):163-70. PubMed ID: 12847992
[TBL] [Abstract][Full Text] [Related]
12. Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial.
Lindor KD; Kowdley KV; Heathcote EJ; Harrison ME; Jorgensen R; Angulo P; Lymp JF; Burgart L; Colin P
Hepatology; 2004 Mar; 39(3):770-8. PubMed ID: 14999696
[TBL] [Abstract][Full Text] [Related]
13. Association between insulin resistance and apolipoprotein B in normoglycemic Koreans.
Sung KC; Hwang ST
Atherosclerosis; 2005 May; 180(1):161-9. PubMed ID: 15823289
[TBL] [Abstract][Full Text] [Related]
14. Treatment of NASH with ursodeoxycholic acid: pro.
Ratziu V
Clin Res Hepatol Gastroenterol; 2012 Sep; 36 Suppl 1():S41-5. PubMed ID: 23141893
[TBL] [Abstract][Full Text] [Related]
15. Effects of ursodeoxycholic acid and/or low-calorie diet on steatohepatitis in rats with obesity and hyperlipidemia.
Fan JG; Zhong L; Tia LY; Xu ZJ; Li MS; Wang GL
World J Gastroenterol; 2005 Apr; 11(15):2346-50. PubMed ID: 15818751
[TBL] [Abstract][Full Text] [Related]
16. Effect of garlic powder tablet on carotid intima-media thickness in patients with coronary artery disease: a preliminary randomized controlled trial.
Mahdavi-Roshan M; Zahedmehr A; Mohammad-Zadeh A; Sanati HR; Shakerian F; Firouzi A; Kiani R; Nasrollahzadeh J
Nutr Health; 2013 Apr; 22(2):143-55. PubMed ID: 25573347
[TBL] [Abstract][Full Text] [Related]
17. Hepatic apolipoprotein A-I gene expression in patients with cholesterol gallstones treated with ursodeoxycholic acid.
Méndez-Sánchez N; Panduro A; Murguía D; Rincón AR; Uribe M
Ann Hepatol; 2002; 1(2):85-9. PubMed ID: 15115973
[TBL] [Abstract][Full Text] [Related]
18. Heterogeneous responsiveness of normolipemic women to n-3 long chain fatty acid supplementation. Changes in serum lipids and apoproteins.
Sánchez-Muniz FJ; Bastida S; Quintas E; Merinero MC; Rodríguez-Gil S
Rev Esp Fisiol; 1997 Dec; 53(4):349-54. PubMed ID: 9542772
[TBL] [Abstract][Full Text] [Related]
19. Improvement in non-alcoholic fatty liver disease severity is associated with a reduction in carotid intima-media thickness progression.
Bhatia L; Scorletti E; Curzen N; Clough GF; Calder PC; Byrne CD
Atherosclerosis; 2016 Mar; 246():13-20. PubMed ID: 26748347
[TBL] [Abstract][Full Text] [Related]
20. Ursodeoxycholic acid and atorvastatin in the treatment of nonalcoholic steatohepatitis.
Kiyici M; Gulten M; Gurel S; Nak SG; Dolar E; Savci G; Adim SB; Yerci O; Memik F
Can J Gastroenterol; 2003 Dec; 17(12):713-8. PubMed ID: 14679419
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
